소개글
통풍 치료제인 Lesinurad에 관한 ppt 자료입니다.
인트로와 약의 정보 및 임상 과정으로 구성되어 있으며,
관련 약품과 약효 임상 결과를 확인하실 수 있습니다.
목차
1.Introduction
2.Drug information
3.Clinical Trial
본문내용
WHAT IS GOUT
Gout
caused?by?abnormally?elevated?levels?of?uric?acid??in?the blood (sUA *> 6.8mg/dL ) resulting in a build-up uric acid crystals throughout the body
* sUA :serum uric acid
Hyperuricemia
linked to elevated hypertension in adults and children
increased mortality in Chronic Kidney Disease and possibly other cardiovascular risk factors, including elevated C-Reactive Protein
Increasing incidence and severity in US approximately 8 million patients
WHAT IS GOUT
HOW TO TREAT
Two?goals?for?treatment?of?hyperuricemia?/gout
Acute?treatment?for?inflammation
NSAIDS?,?colchicine,?corticosteroid, IL?1?inhibitor
Chronic?treatment to?lower?serum?uric?acid
Uricosurics :?benzobromarone?,?probenecid, sulfinpyrazone
Xanthine?oxidase?inhibitors :?allopurinol,?febuxostat?(FBX)
Uricase :?pegloticase
참고 자료
Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopurinol or Febuxostat, January 2010
Ken Okamoto and Takeshi Nishino, Crystral structures of mammalian xanthine oxidoreductase bound with various inhibitor: allopurinol, febuxostat, and FYX-051
L-T.Yeh 외 8명, Safety, phamacokinetics, and serum uric acid lowering effect of RDEA594, a novel uricosuric agent, in healthy volunteers, June 10, 2009
Z.shen 외 9명, Lesinurad , A novel URAT1 Inhibitor, Shows Additive Serum Urate Lowring Effecrs in Combination with Xanthine Oxidase Inhibitor Febuxostat
X Yang 외 7명, Evaluation of drug-drug interacion potential between RDEA594, Allopurinol and Febuxostat in preclinical species, October 16, 2009
Sasha B. Coffiner, Ardea seeks partner for RDEA 594 in gout, executive says; may be effective in combination with febuxustat, allopurinol ? rheumatologists, July 2, 2010
R. Fleischmann 외 9명, Lesinurad (RDEA594), A Novel Oral Uricosuric Agent, in combination with Febuxostat Shows Significant Additive Urate Lowering Effects in Gout Subjects with 100% Response Achieved for All Combination Dose Regimens, May 25, 2011